Neurolex is being transitioned to a new system and is currently not accepting new additions. If you have additions or questions please contact us at [email protected], or submit an issue to the github issue tracker at


From NeuroLex

Jump to: navigation, search
Comment taken from DrugBank
Curator Ab +
DefiningCitation  +
Definition Synthetic decapeptide antagonist to gonado Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. Pharmacology: Used in the palliative treatment of advanced prostate cancer. Abarelix is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis. Mechanism of action: Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. Drug type: Approved. Biotech. Investigational. Withdrawn. Drug category: Anti-Testosterone Agents. Antineoplastic Agents Testosterone Agents. Antineoplastic Agents
Has role Drug +
Id DB00106  +
Label Abarelix  +
Modification dateThis property is a special property in this wiki. 14 April 2014 20:29:19  +
ModifiedDate 14 April 2014  +
RelatedTo Gonadotrophin-releasing hormone +
SuperCategory Molecular entity  +
Synonym abarelix  +, Plenaxis  +, Plenaxis (Praecis Pharmaceuticals)  +
Categories Molecular entity
hide properties that link here 
  No properties link to this page.


Enter the name of the page to start browsing from.

*Note: Neurolex imports many terms and their ids from existing community ontologies, e.g., the Gene Ontology. Neurolex, however, is a dynamic site and any content beyond the identifier should not be presumed to reflect the content or views of the source ontology. Users should consult with the authoritative source for each ontology for current information.